Skip to content

Bio-Techne TECH Payments to Acquire Equity Securities, FV-NI

Payments to Acquire Equity Securities, FV-NI at other companies

Lantheus Holdings logo
Lantheus HoldingsLNTH

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$9.07B-11.8%
Enterprise value$9.15B-13.6%
P/E60.6×+13.6×
P/S7.5×-1.0×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquitySecuritiesFvNi.

The official record: Bio-Techne’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's payments to acquire equity securities, fv-ni.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Techne's payments to acquire equity securities, FV-NI?
Bio-Techne (TECH) reported payments to acquire equity securities, FV-NI of $15M in Q3 2024.